Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.

Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.

Cancer. 2018 Oct 5. doi: 10.1002/cncr.31731. [Epub ahead of print]

PMID:
30289174
2.

Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.

J Natl Cancer Inst. 2018 Sep 18. doi: 10.1093/jnci/djy147. [Epub ahead of print]

PMID:
30239769
3.

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.

Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA.

Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3.

PMID:
30224110
4.

Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer.

Jagsi R, Ward KC, Abrahamse PH, Wallner LP, Kurian AW, Hamilton AS, Katz SJ, Hawley ST.

Cancer. 2018 Jul 23. doi: 10.1002/cncr.31532. [Epub ahead of print]

PMID:
30033631
5.

Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.

Pollom EL, Qian Y, Chin AL, Dirbas FM, Asch SM, Kurian AW, Horst KC, Tsai CJ.

Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31747. [Epub ahead of print]

PMID:
29992582
6.

Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.

Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP.

JAMA Surg. 2018 Jul 3. doi: 10.1001/jamasurg.2018.2001. [Epub ahead of print]

PMID:
29971344
7.

Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations.

Kwong A, Shin VY, Ma ES, Chan CT, Ford JM, Kurian AW, Tai E.

Hong Kong Med J. 2018 Jun;24 Suppl 3(3):4-6. No abstract available.

8.

Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients.

Rafat M, Aguilera TA, Vilalta M, Bronsart LL, Soto LA, von Eyben R, Golla MA, Ahrari Y, Melemenidis S, Afghahi A, Jenkins MJ, Kurian AW, Horst KC, Giaccia AJ, Graves EE.

Cancer Res. 2018 Aug 1;78(15):4241-4252. doi: 10.1158/0008-5472.CAN-17-3623. Epub 2018 Jun 7.

PMID:
29880480
9.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.

JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

PMID:
29801090
10.

Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy.

Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, Kurian AW, Daniel BL, Li R.

Radiology. 2018 Jul;288(1):26-35. doi: 10.1148/radiol.2018172462. Epub 2018 May 1.

PMID:
29714680
11.

Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies.

Chu LW, John EM, Yang B, Kurian AW, Zia Y, Yu K, Ingles SA, Stanczyk FZ, Hsing AW.

PLoS One. 2018 Apr 11;13(4):e0195666. doi: 10.1371/journal.pone.0195666. eCollection 2018.

12.

Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Howlader N, Cronin KA, Kurian AW, Andridge R.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28.

PMID:
29593010
13.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.

Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.

PMID:
29581131
14.

Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):9S-23S. doi: 10.1177/0272989X17700624.

PMID:
29554466
15.

Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.

Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW.

J Clin Oncol. 2018 Apr 20;36(12):1218-1224. doi: 10.1200/JCO.2017.76.2369. Epub 2018 Mar 12.

PMID:
29528794
16.

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.

Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.

Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.

17.

Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.

Shumway DA, McLeod CM, Morrow M, Li Y, Kurian AW, Sabolch A, Hamilton AS, Ward KC, Katz SJ, Hawley ST, Jagsi R.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1237-1245. doi: 10.1016/j.ijrobp.2018.01.020. Epub 2018 Jan 9.

PMID:
29439886
18.

Patient communication of cancer genetic test results in a diverse population.

Ricker CN, Koff RB, Qu C, Culver J, Sturgeon D, Kingham KE, Lowstuter K, Chun NM, Rowe-Teeter C, Lebensohn A, Levonian P, Partynski K, Lara-Otero K, Hong C, Petrovchich IM, Mills MA, Hartman AR, Allen B, Ladabaum U, McDonnell K, Ford JM, Gruber SB, Kurian AW, Idos GE.

Transl Behav Med. 2018 Jan 29;8(1):85-94. doi: 10.1093/tbm/ibx010.

PMID:
29385580
19.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

20.

Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.

Kurian AW, Bondarenko I, Jagsi R, Friese CR, McLeod MC, Hawley ST, Hamilton AS, Ward KC, Hofer TP, Katz SJ.

J Natl Cancer Inst. 2018 May 1;110(5):493-500. doi: 10.1093/jnci/djx239.

PMID:
29237009
21.

Treatment decisions and employment of breast cancer patients: Results of a population-based survey.

Jagsi R, Abrahamse PH, Lee KL, Wallner LP, Janz NK, Hamilton AS, Ward KC, Morrow M, Kurian AW, Friese CR, Hawley ST, Katz SJ.

Cancer. 2017 Dec 15;123(24):4791-4799. doi: 10.1002/cncr.30959. Epub 2017 Oct 9.

PMID:
28990155
22.

Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.

Lin CY, Carneal EE, Lichtensztajn DY, Gomez SL, Clarke CA, Jensen KC, Kurian AW, Allison KH.

Am J Clin Pathol. 2017 Sep 1;148(3):199-207. doi: 10.1093/ajcp/aqx063.

23.

What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?

Lee KL, Janz NK, Zikmund-Fisher BJ, Jagsi R, Wallner LP, Kurian AW, Katz SJ, Abrahamse P, Hawley ST.

Med Decis Making. 2018 Jan;38(1):95-106. doi: 10.1177/0272989X17724441. Epub 2017 Aug 17.

PMID:
28814131
24.

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.

Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, Ford JM, Kurian AW.

Genet Med. 2018 Feb;20(2):234-239. doi: 10.1038/gim.2017.96. Epub 2017 Jul 27.

PMID:
28749474
25.

Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.

Wu J, Li B, Sun X, Cao G, Rubin DL, Napel S, Ikeda DM, Kurian AW, Li R.

Radiology. 2017 Nov;285(2):401-413. doi: 10.1148/radiol.2017162823. Epub 2017 Jul 14.

PMID:
28708462
26.

Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?

Katz SJ, Hawley ST, Bondarenko I, Jagsi R, Ward KC, Hofer TP, Kurian AW.

Breast Cancer Res Treat. 2017 Oct;165(3):751-756. doi: 10.1007/s10549-017-4377-3. Epub 2017 Jul 8.

27.

Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management.

Morrow M, Abrahamse P, Hofer TP, Ward KC, Hamilton AS, Kurian AW, Katz SJ, Jagsi R.

JAMA Oncol. 2017 Oct 1;3(10):1352-1357. doi: 10.1001/jamaoncol.2017.0774.

28.

The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.

Afghahi A, Kurian AW.

Curr Treat Options Oncol. 2017 May;18(5):27. doi: 10.1007/s11864-017-0468-y. Review.

PMID:
28439798
29.

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.

Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ.

J Clin Oncol. 2017 Jul 10;35(20):2232-2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12.

30.

Genetics of triple-negative breast cancer: Implications for patient care.

Afghahi A, Telli ML, Kurian AW.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23. Review.

PMID:
28340968
31.

Dynamic strategy for personalized medicine: An application to metastatic breast cancer.

Chen X, Shachter RD, Kurian AW, Rubin DL.

J Biomed Inform. 2017 Apr;68:50-57. doi: 10.1016/j.jbi.2017.02.012. Epub 2017 Feb 21.

32.

Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA.

J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. Epub 2017 Feb 10.

33.

Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .

Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R.

JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918. No abstract available.

34.

Treatment-associated toxicities reported by patients with early-stage invasive breast cancer.

Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, Hamilton AS, Ward KC, Kurian AW, Katz SJ, Hofer TP.

Cancer. 2017 Jun 1;123(11):1925-1934. doi: 10.1002/cncr.30547. Epub 2017 Jan 24.

35.

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.

Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML.

Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.

36.

Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways.

Wu J, Cui Y, Sun X, Cao G, Li B, Ikeda DM, Kurian AW, Li R.

Clin Cancer Res. 2017 Jul 1;23(13):3334-3342. doi: 10.1158/1078-0432.CCR-16-2415. Epub 2017 Jan 10.

37.

Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.

Kurian AW, Friese CR, Bondarenko I, Jagsi R, Li Y, Hamilton AS, Ward KC, Katz SJ.

JAMA Oncol. 2017 Mar 1;3(3):391-397. doi: 10.1001/jamaoncol.2016.5652.

38.

The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.

Li Y, Kurian AW, Bondarenko I, Taylor JMG, Jagsi R, Ward KC, Hamilton AS, Katz SJ, Hofer TP.

Breast Cancer Res Treat. 2017 Feb;161(3):587-595. doi: 10.1007/s10549-016-4086-3. Epub 2016 Dec 23.

39.

Recurrence risk perception and quality of life following treatment of breast cancer.

Hawley ST, Janz NK, Griffith KA, Jagsi R, Friese CR, Kurian AW, Hamilton AS, Ward KC, Morrow M, Wallner LP, Katz SJ.

Breast Cancer Res Treat. 2017 Feb;161(3):557-565. doi: 10.1007/s10549-016-4082-7. Epub 2016 Dec 21.

40.

Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer.

Jagsi R, Hawley ST, Griffith KA, Janz NK, Kurian AW, Ward KC, Hamilton AS, Morrow M, Katz SJ.

JAMA Surg. 2017 Mar 1;152(3):274-282. doi: 10.1001/jamasurg.2016.4749.

41.

The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence.

Janz NK, Li Y, Zikmund-Fisher BJ, Jagsi R, Kurian AW, An LC, McLeod MC, Lee KL, Katz SJ, Hawley ST.

Breast Cancer Res Treat. 2017 Feb;161(3):525-535. doi: 10.1007/s10549-016-4076-5. Epub 2016 Dec 9.

42.

Synergistic drug combinations from electronic health records and gene expression.

Low YS, Daugherty AC, Schroeder EA, Chen W, Seto T, Weber S, Lim M, Hastie T, Mathur M, Desai M, Farrington C, Radin AA, Sirota M, Kenkare P, Thompson CA, Yu PP, Gomez SL, Sledge GW Jr, Kurian AW, Shah NH.

J Am Med Inform Assoc. 2017 May 1;24(3):565-576. doi: 10.1093/jamia/ocw161.

43.

Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'.

Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML.

Br J Cancer. 2017 Jan;116(3):e2. doi: 10.1038/bjc.2016.396. Epub 2016 Dec 6. No abstract available.

44.

Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?

Wang A, Wakelee HA, Aragaki AK, Tang JY, Kurian AW, Manson JE, Stefanick ML.

Curr Atheroscler Rep. 2016 Dec;18(12):72. Review.

PMID:
27796821
45.

Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.

Friese CR, Li Y, Bondarenko I, Hofer TP, Ward KC, Hamilton AS, Deapen D, Kurian AW, Katz SJ.

Cancer. 2017 Jan 1;123(1):43-51. doi: 10.1002/cncr.30324. Epub 2016 Oct 24.

46.

Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013.

Kurian AW, Canchola AJ, Gomez SL, Clarke CA.

Breast Cancer Res Treat. 2016 Nov;160(2):333-338. Epub 2016 Sep 24.

47.

Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.

Wapnir IL, Kurian AW, Lichtensztajn DY, Clarke CA, Gomez SL.

Ann Surg. 2017 Aug;266(2):353-360. doi: 10.1097/SLA.0000000000001972.

48.

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.

Tao L, Chu L, Wang LI, Moy L, Brammer M, Song C, Green M, Kurian AW, Gomez SL, Clarke CA.

Cancer Causes Control. 2016 Sep;27(9):1127-38. doi: 10.1007/s10552-016-0791-9. Epub 2016 Aug 5.

PMID:
27496200
49.

Statin use and all-cancer survival: prospective results from the Women's Health Initiative.

Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML.

Br J Cancer. 2016 Jun 28;115(1):129-35. doi: 10.1038/bjc.2016.149. Epub 2016 Jun 9.

50.

Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information.

Kurian AW, Antoniou AC, Domchek SM.

Am Soc Clin Oncol Educ Book. 2016;35:44-56. doi: 10.14694/EDBK_158817.

Supplemental Content

Loading ...
Support Center